1. Home
  2. ALOT vs BTAI Comparison

ALOT vs BTAI Comparison

Compare ALOT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AstroNova Inc.

ALOT

AstroNova Inc.

N/A

Current Price

$8.65

Market Cap

56.7M

Sector

Technology

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALOT
BTAI
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.7M
49.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ALOT
BTAI
Price
$8.65
$1.60
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$32.80
AVG Volume (30 Days)
32.2K
463.9K
Earning Date
12-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$150,340,000.00
$752,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$441.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.96
$1.17
52 Week High
$13.38
$9.26

Technical Indicators

Market Signals
Indicator
ALOT
BTAI
Relative Strength Index (RSI) 60.08 38.94
Support Level $8.35 $1.50
Resistance Level $8.83 $1.89
Average True Range (ATR) 0.32 0.10
MACD 0.14 -0.02
Stochastic Oscillator 89.41 19.28

Price Performance

Historical Comparison
ALOT
BTAI

About ALOT AstroNova Inc.

AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: